Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Cash Flow (2022 - 2025)

Stoke Therapeutics has reported Net Cash Flow over the past 4 years, most recently at $826000.0 for Q4 2025.

  • Quarterly results put Net Cash Flow at $826000.0 for Q4 2025, up 103.79% from a year ago — trailing twelve months through Dec 2025 was -$43.8 million (up 30.67% YoY), and the annual figure for FY2025 was -$43.8 million, up 30.67%.
  • Net Cash Flow for Q4 2025 was $826000.0 at Stoke Therapeutics, up from -$18.2 million in the prior quarter.
  • Over the last five years, Net Cash Flow for STOK hit a ceiling of $146.8 million in Q1 2025 and a floor of -$173.3 million in Q2 2025.
  • Median Net Cash Flow over the past 4 years was -$961500.0 (2022), compared with a mean of -$3.8 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 1986.41% in 2024 and later skyrocketed 1241.69% in 2025.
  • Stoke Therapeutics' Net Cash Flow stood at $160000.0 in 2022, then skyrocketed by 815.62% to $1.5 million in 2023, then tumbled by 1588.46% to -$21.8 million in 2024, then soared by 103.79% to $826000.0 in 2025.
  • The last three reported values for Net Cash Flow were $826000.0 (Q4 2025), -$18.2 million (Q3 2025), and -$173.3 million (Q2 2025) per Business Quant data.